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1. Introduction 
The nanomedicine which is the application of technologies on the scale of 1 to 500 nm to 
diagnose and treat diseases, it has become a very relevant topic nowadays. During the last 
century, there has been a lot of new research and patents regarding nanomedicine in health 
sciences [1]. The objective of nanomedicine is to diagnose and preserve the health without 
side effects with noninvasive treatments. To reach these goals, nanomedicine offers a lot of 
new tools and capabilities. The manipulation that nanomedicine provides to the drugs and 
other materials in the nanometer scale can change the basic properties and bioactivity of 
materials. The solubility, increment in surface area, control release and site-targeted delivery 
are some characteristics that nanotechnology can manipulate on drug delivery systems. 
Nanotechnology applied to health sciences contains new devices used in surgery, new chips 
for better diagnostics, new materials for substituting body structures and some structures 
capable to carry drugs through the body for treatment of a lot of diseases. These structures 
can be made of a lot of different materials and they are very different in structure and 
chemical nature. All these nanostructures are called nanocarriers and they can be 
administrated into the organisms by topical and transdermal routes [2]. Nanocarriers are a 
powerful weapon against a lot of illnesses since they are so small to be detected by immune 
system and they can deliver the drug in the target organ. For that reason, drug doses using 
nanocarriers and side effects decrease a lot. 
The idea for using these tiny systems is not as new as we think but the use of nanocarriers in 
pharmaceutical products is not frequent, since the technology is expensive for certain types 
of nanoparticles and because nanocarriers need to be evaluated for demonstrating they do 
not have toxic effects. Nowadays the controversy of biological effects due to nanostructures 
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is an open discussion, in one hand, the nanotechnologist continue making new and more 
sophisticated nanocarriers and in the other hand, toxicologist continue evaluating possible 
damaging effects. 
Whatever it happens, nanotechnology is the new era and nanomedicine cannot be taking off. 
New nanocarriers will be created and the entire scientist working in nanomedicine bet for it 
to be the cure of diseases that in this moment are difficult to deal with [3] 
The application of preparations to the skin for medical purposes is as old as the history of 
medicine itself, with references to the use of ointments and salves found in the records of 
Babylonian and Egyptian medicine. The historical development of permeation research is 
well described by Hadgraft & Lane [4]. Over time, the skin has become an important route 
for drug delivery in which topical, regional or systemic effects are desired. Nevertheless, 
skin constitutes an excellent barrier and presents difficulties for the transdermal delivery of 
therapeutic agents, since few drugs possess the characteristics required to permeate across 
the stratum corneum in sufficient quantities to reach a therapeutic concentration in the 
blood. In order to enhance drug transdermal absorption different methodologies have been 
investigated developed and patented [5,6]. Improvement in physical permeation-
enhancement technologies has led to renewed interest in transdermal drug delivery. Some 
of these novel advanced transdermal permeation enhancement technologies include: 
iontophoresis, electroporation, ultrasound, microneedles to open up the skin and more 
recently the use of transdermal nanocarriers [3,7-10]. 
A number of excellent reviews that have been published contain detailed discussions 
concerning many aspects of transdermal nanocarriers [11-17]. The present chapter shows an 
updated overview of the use of submicron particles and other nanostructures in the 
pharmaceutical field, specifically in the area of topical and transdermal drugs. This focus is 
justified due to the magnitude of the experimental data available with the use of these 
nanocarriers. The development of submicron particles and other nanostructures in the 
pharmaceutical and cosmetic fields has been emerged in the last decades for designing best 
formulations for application through the skin [18-21]. 
2. The skin 
The skin is the largest organ of the body [22-24], accounting for more than 10% of body 
mass, and the one that enables the body to interact more intimately with its environment. 
Essentially, the skin consists of four layers: The SC, that is the outer layer of the skin (non-
viable epidermis), and forms the rate-controlling barrier for diffusion for almost all 
compounds. It is composed of dead flattened, keratin-rich cells, the corneocytes. These 
dense cells are surrounded by a complex mixture of intercellular lipids, namely, ceramides, 
free fatty acids, cholesterol, and cholesterol sulphate. Their most important feature is that 
they are structured as ordered bilayer arrays [25-28]. The other layers are: the remaining 
layers of the epidermis (viable epidermis), the dermis, and the subcutaneous tissue (Figure 
1). There are also several associated appendages: hair follicles sweat ducts, glands and nails 
[29,30]. 
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Many agents are applied to the skin either deliberately or accidentally, with either beneficial 
or deleterious outcomes. The main interest in dermal absorption assessment is related to: a) 
Local effects in dermatology (e.g., corticosteroids for dermatitis); b) transport through the 
skin seeking a systemic effect (e.g., nicotine patches, hormonal drug patches, etc.) [31]; c) 
surface effects (e.g., sunscreens, cosmetics, and anti-infectives) [32,33]; d) targeting of deeper 
tissues (e.g., nonsteroidal anti-inflammatory agents) [34-37]; and e) unwanted absorption 
(e.g., solvents in the workplace, pesticides or allergens) [38,39]. 
 
Figure 1. Schematic representation of skin layer. 
2.1. Epidermis 
2.1.1. Stratum corneum 
The stratum corneum is the heterogeneous outermost layer of the epidermis and is 
approximately 10-20 µm thick. The stratum corneum consists of about 15 to 25 layers of 
flattened, stacked, hexagonal, and cornified cells embedded in an intercellular matrix of 
lipids. These lipid domains form a continuous structure so they are considered to play a 
crucial role in the maintenance of the skin barrier that helps avoid transepidermal water 
loss. Each cell is approximately 40 µm in diameter and 0.5 µm thick [40].  
The stratum corneum barrier properties may be partly related to its very high density (1.4 
g/cm3 in the dry state) and its low hydration of 15–20 %, compared with the usual 70 % for 
the body. Each stratum corneum cell is composed mainly of insoluble bundled keratins (70 
%) and lipid (20 %) encased in a cell envelope, accounting for about 5% of the stratum 
corneum weight. The permeability barrier is located within the lipid bilayers in the 
intercellular spaces of the stratum corneum [6-8] and consists of ceramides (40–50%), fatty 
acids (15–25%), cholesterol (20–25%) and cholesterol sulphate (5–10 %) [41-45].  
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The barrier function is further facilitated by the continuous desquamation of this horny 
layer with a total turnover of the stratum corneum occurring once every 2–3 weeks. The 
stratum corneum functions as a barrier are to prevent the loss of internal body components, 
particularly water, to the external environment. The cells of the stratum corneum originate 
in the viable epidermis and undergo many morphological changes before desquamation. 
Thus, the epidermis consists of several cell strata at varying levels of differentiation.  
The origins of the cells of the epidermis lie in the basal lamina between the dermis and 
viable epidermis. In this layer there are melanocytes, Langerhans cells, Merkel cells, and two 
major keratinic cell types: the first functioning as stem cells having the capacity to divide 
and produce new cells; the second serving to anchor the epidermis to the basement 
membrane [46]. The basement membrane is 50–70 nm thick and consists of two layers, the 
lamina densa and lamina lucida, which comprise mainly proteins, such as type IV collagen, 
aminin, nidogen and fibronectin. Type IV collagen is responsible for the mechanical stability 
of the basement membrane, whereas laminin and fibronectin are involved with the 
attachment between the basement membrane and the basal keratinocytes. The cells of the 
basal lamina are attached to the basement membrane by hemidesmosomes, which are found 
on the ventral surface of basal keratinocytes [47]. Hemidesmosomes appear to comprise 
three distinct protein groups: two of which are bullous pemphigoid antigens (BPAG1 and 
BPAG2), and the other epithelial cellspecific integrins [48-50]. BPAG1 is associated with the 
organization of the cytoskeletal structure and forms a link between the hemidesmosome 
structure and the keratin intermediate filaments. The integrins are transmembrane receptors 
that mediate attachment between the cell and the extracellular matrix. Human epidermal 
basal cells contain integrins α2β1, α3β1 and α6β4. Integrin α6β4 and BPAG2 appear to be the 
major hemidesmosomal protein contributors to the anchoring of the keratinocyte, spanning 
from the keratin intermediate filament, through the lamina lucida, to the lamina densa of the 
basement membrane [51]. In the lamina densa, these membrane-spanning proteins interact 
with the protein laminin-5 which, in turn, is linked to collagen VII, the major constituent of 
the anchoring fibrils within the dermal matrix. It has also been suggested that both BPAG2 
and integrin α6β4 mediate in the signal transductions required for hemidesmosome 
formation and cell differentiation and proliferation. Integrin α3β1 is associated with actin 
and may be linked with laminin-5. Epidermal wounding results in an up-regulation of these 
proteins that appears to be involved with cell motility and spreading. The importance of 
maintaining a secure link between the basal lamina cells and the basement membrane is 
obvious, and the absence of this connection results in chronic blistering diseases such as 
pemphigus and epidermolysis bullosa.  
2.2. Dermis 
The dermis is about 0.1–0.5 cm thick and consists of collagenous (70 %) and elastin fibres. In 
the dermis, glycosaminoglycans or acid mucopolysaccharides, are covalently linked to 
peptide chains to form proteoglycans, the ground substance that promotes the elasticity of 
the skin. The main cells present are the fibroblasts, which produce the connective tissue 
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components of collagen, laminin, fibronectin and vitronectin; mast cells, which are involved 
in the immune and inflammatory responses; and melanocytes involved in the production of 
the pigment melanin [51]. Nerves, blood vessels and lymphatic vessels are also present in 
the dermis.  
Contained within the dermis is an extensive vascular network providing for the skin 
nutrition, repair, and immune responses for the rest of the body, heat exchange, immune 
response, and thermal regulation. Skin blood vessels derive from those in the subcutaneous 
tissues (hypodermis), with an arterial network supplying the papillary layer, the hair 
follicles, the sweat and apocrine glands, the subcutaneous area, as well as the dermis itself. 
These arteries feed into arterioles, capillaries, venules, and, thence, into veins. Of particular 
importance in this vascular network is the presence of arteriovenous anastomoses at all 
levels in the skin. These arteriovenous anastomoses, which allow a direct shunting of up to 
60% of the skin blood flow between the arteries and veins, thereby avoiding the fine 
capillary network, are critical to the skin’s functions of heat regulation and blood vessel 
control. Blood flow changes are most evident in the skin in relation to various physiological 
responses and include psychological effects, such as shock (‘‘draining of color from the 
skin’’) and embarrassment (‘‘blushing’’), temperature effects, and physiological responses to 
exercise, hemorrhage, and alcohol consumption.  
The lymphatic system is an important component of the skin in regulating its interstitial 
pressure, mobilization of defense mechanisms, and in waste removal. It exists as a dense, 
flat meshwork in the papillary layers of the dermis and extends into the deeper regions of 
the dermis. Also present in the dermis are a number of different types of nerve fibers 
supplying the skin, including those for pressure, pain, and temperature [52]. Epidermal 
appendages such as hair follicles and sweat glands are embedded in the dermis [53]. 
2.3. Hypodermis 
The deepest layer of the skin is the subcutaneous tissue or hypodermis. The hypodermis acts 
as a heat insulator, a shock absorber, and an energy storage region. This layer is a network 
of fat cells arranged in lobules and linked to the dermis by interconnecting collagen and 
elastin fibers. As well as fat cells (possibly 50% of the body’s fat); the other main cells in the 
hypodermis are fibroblasts and macrophages. One of the major roles of the hypodermis is to 
carry the vascular and neural systems for the skin. It also anchors the skin to underlying 
muscle. Fibroblasts and adipocytes can be stimulated by the accumulation of interstitial and 
lymphatic fluid within the skin and subcutaneous tissue [54]. The total thickness of skin is 
about 2–3 mm, but the thickness of the stratum corneum is only about 10–15 µm. 
2.4. Skin appendages 
There are four skin appendages: the hair follicles with their associated sebaceous glands, 
eccrine and apocrine sweat glands, and the nails, but these occupy only about 0.1 % of the 
total human skin surface.  
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The pilosebaceous follicles have about 10 to 20 % of the resident flora and cannot be 
decontaminated by scrubbing. The hair follicles are distributed across the entire skin surface 
with the exception of the soles of the feet, the palms of the hand and the lips. A smooth 
muscle, the erector pilorum, attaches the follicle to the dermal tissue and enables hair to 
stand up in response to fear. Each follicle is associated with a sebaceous gland that varies in 
size from 200 to 2000 µm in diameter. The sebum secreted by this gland consisting of 
triglycerides, free fatty acids, and waxes, protects and lubricates the skin as well as 
maintaining a pH of about 5. Sebaceous glands are absent on the palms, soles and nail beds. 
Sweat glands or eccrine glands respond to temperature via parasympathetic nerves, except 
on palms, soles and axillae, where they respond to emotional stimuli via sympathetic nerves 
[51]. The eccrine glands are epidermal structures that are simple, coiled tubes arising from a 
coiled ball, of approximately 100 µm in diameter, located in the lower dermis. It secretes a 
dilute salt solution with a pH of about 5, this secretion being stimulated by temperature-
controlling determinants, such as exercise and high environmental temperature, as well as 
emotional stress through the autonomic (sympathetic) nervous system. These glands have a 
total surface area of about 1/10,000 of the total body surface. The apocrine glands are limited 
to specific body regions and are also coiled tubes. These glands are about ten times the size 
of the eccrine ducts, extend as low as the subcutaneous tissues and are paired with hair 
follicles.  
Nail function is considered as protection. Nail plate consists of layers of flattened 
keratinized cells fused into a dense but elastic mass. The cells of the nail plate originate in 
the nail matrix and grow distally at a rate of about 0.1 mm/day. In the keratinization process 
the cells undergo shape and other changes, similar to those experienced by the epidermal 
cells forming the stratum corneum. This is not surprising because the nail matrix basement 
membrane shows many biochemical similarities to the epidermal basement membrane 
[55,56]. Thus, the major components are highly folded keratin proteins with small amounts 
of lipid (0.1–1.0%). The principal plasticizer of the nail plate is water, which is normally 
present at a concentration of 7–12 %. 
3. Skin functions 
Many of the functions of the skin can be classified as essential to survival of the body bulk of 
mammals and humans in a relatively hostile environment. In a general context, these 
functions can be classified as a protective, maintaining homeostasis or sensing. The 
importance of the protective and homeostatic role allows the survival of humans in an 
environment of variable temperature; water content (humidity and bathing); and the 
presence of environmental dangers, such as chemicals, bacteria, allergens, fungi and 
radiation. In a second context, the skin is a major organ for maintaining the homeostasis of 
the body, especially in terms of its composition, heat regulation, blood pressure control, and 
excretory roles. It has been argued that the basal metabolic rate of animals differing in size 
should be scaled to the surface area of the body to maintain a constant temperature through 
the skin’s thermoregulatory control [57]. Third, the skin is a major sensory organ in terms of 
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sensing environmental influences, such as heat, pressure, pain, allergen, and microorganism 
entry. Finally, the skin is an organ that is in a continual state of regeneration and repair. To 
fulfill each of these functions, the skin must be tough, robust, and flexible, with effective 
communication between each of its intrinsic components mentioned above. 
The stratum corneum also functions as a barrier to prevent the loss of internal body 
components, particularly water, to the external environment. The epidermis plays a role in 
temperature, pressure, and pain regulation. 
Appendage functions are following: hair follicle and sebaceous gland fulfill with protect 
(hair) and lubricate (sebum), eccrine and apocrine glands have the functions of cooling and 
vestigial secondary sex gland, respectively; and nails has the function of to protect.The 
hypodermis acts as a heat insulator, a shock absorber and an energy storage region. One of 
the major roles of the hypodermis is to carry the vascular and neural systems for the skin. 
4. Routes of drug penetration through the skin  
The determination of penetration pathways of topically applied substances into the skin is 
the subject of several investigations. The permeation of drugs through the skin includes the 
diffusion through the intact epidermis y through the skin appendages. These skin 
appendages are hair follicles and sweat glands which form shunt pathways through the 
intact epidermis, occupying only 0.1% of the total human skin [58]. It is known drug 
permeation through the skin is usually limited by the stratum corneum. Two pathways 
through the intact barrier may be identified, the intercellular and transcellular route (Figure 
2): 
a. The intercellular lipid route is between the corneocytes. 
Interlamellar regions in the stratum corneum, including linker regions, contain less ordered 
lipids and more flexible hydrophobic chains. This is the reason of the non-planar spaces 
between crystalline lipid lamellae and their adjacent cells outer membrane. Fluid lipids in 
skin barrier are crucially important for transepidermal diffusion of the lipidic and 
amphiphilic molecules, occupying those spaces for the insertion and migration through 
intercellular lipid layers of such molecules [59,60]. The hydrophilic molecules diffuse 
predominantly “laterally” along surfaces of the less abundant, water filled inter-lamellar 
spaces or through such volumes; polar molecules can also use the free space between a 
lamella and a corneocyte outer membrane to the same end [61]. 
b. The transcellular route contemplates the crossing through the corneocytes and the 
intervening lipids [24]. 
Intracellular macromolecular matrix within the stratum corneum abounds in keratin, which 
does not contribute directly to the skin diffusive barrier but supports mechanical stability 
and thus intactness of the stratum corneum. Transcellular diffusion is practically 
unimportant for transdermal drug transport [62]. The narrow aqueous transepidermal 
pathways have been observed using confocal laser scanning microscopy (CLSM). Here 
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regions of poor cellular and intercellular lipid packing coincide with wrinkles on skin 
surface and are simultaneously the sites of lowest skin resistance to the transport of 
hydrophilic entities. This lowest resistance pathway leads between clusters of corneocytes at 
the locations where such cellular groups show no lateral overlap. 
The better sealed and more transport resistant is the intra-cluster/inter-corneocyte pathway 
[63]. Hydrophilic conduits have openings between ≥5 µm (skin appendages) and ≤10 nm 
(narrow inter-corneocyte pores). So sweat ducts (≥50 µm), pilosebaceous units (5–70 µm), 
and sebaceous glands (5–15 µm) represent the largest width/lowest resistance end of the 
range. Junctions of corneocytes-clusters and cluster boundaries fall within the range [64]. It 
was determined that the maximally open hydrophilic conduits across skin are 
approximately 20–30 nm wide, including pore penetrant/opener thickness [63]. Another 
studies revealed the width of the negatively charged hydrophilic transepidermal pores 
expanded by electroosmosis to be around of 22–48 nm [65]. Lipophilic cutaneous barrier is 
governed by molecular weight and distribution coefficient rather than molecular size [66]. 
The relative height of cutaneous lipophilic barrier consequently decreases with lipophilicity 
of permeant, but molecules heavier than 400–500 Da are so large permeants to find 
sufficiently wide defects in the intercellular lipidic matrix to start diffusing through the 
lipidic parts of cutaneous barrier [64, 66,67]. 
The contribution to transdermal drug transport can increases with the pathways widening 
or multiplication, for example such that is caused by exposing the stratum corneum to a 
strong electrical (electroporation/iontophoresis), mechanical (sonoporation/sonophoresis), 
thermal stimulus, or suitable skin penetrants [59]. 
Recently, follicular penetration has become a major focus of interest due to the drug 
targeting to the hair follicle is of great interest in the treatment of skin diseases. However 
due to follicular orifices only occupying 0.1% of the total skin surface area, it was assumed 
as a non important route. But a variety of studies shown the hair follicles as could be a way 
to trough the skin [68- 73]. Such follicular pathway also has been proposed for topical 
administration of nanoparticles and microparticles and it has been investigated in porcine 
skin, because in recent studies the results have confirmed the in vitro penetration into the 
porcine hair follicles might be considered similar to those on humans in vivo. After topical 
application of dye sodium fluorescein onto porcine skin mounted in Franz diffusion cells 
with the acceptor compartment beneath the dermis, the fluorescence was detected on the 
surface, within the horny layer, and in most of the follicles confirming the similarity in the 
penetration between porcine and human skin [72]. So nanoparticles have been studied in 
porcine skin revealing in the surface images that polystyrene nanoparticles accumulated 
preferentially in the follicular openings, this distribution was increased in a time-dependent 
manner, and the follicular localization was favored by the smaller particle size [74]. In other 
investigations, it has been shown by differential stripping the influence of size 
microparticles in the skin penetration. It can act as efficient drug carriers or can be utilized 
as follicle blockers to stop the penetration of topically applied substances [73].  
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It has already been postulated that certain molecules can hydrogen bond to groups present 
on the surfaces of follicular pores [75]. However, more studies have to be made in order to 
identify all the molecular properties that influence drug penetration into hair follicles. 
Nowadays, there are currently a number of methods available for quantifying drugs 
localized within the skin or various layers of the skin. To date, a direct, non-invasive 
quantification of the amount of topically applied substance penetrated into the follicles had 
not been possible. Therefore, stripping techniques, tape stripping and cyanoacrylate skin 
surface biopsy have been used to remove the part of the stratum corneum containing dye 
topically applied [76]. Thus, the "differential stripping" has been shown as a new method 
that can be used to study the penetration of topically applied substances into the follicular 
infundibula non-invasively and selectively [20,26,30,76,77].  
 
Figure 2. Schematic representation of penetration routes of drugs throughout the skin. 
5. Advantages and disadvantages of transdermal drug delivery 
Transdermal drug delivery systems offer several important advantages over more 
traditional approaches, in addition to the benefits of avoiding the hepatic first-pass effect, 
and higher patient compliance, the additional advantages and the disadvantages [78-80] that 
transdermal drug delivery offers can be summarized as follows in Table 1. 
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Advantages of transdermal drug delivery Disadvantages of transdermal drug 
delivery 
Longer duration of action  Possibility of local irritation at the site of 
application 
Reduction in dosing frequency Erythema, itching, and local edema can be 
caused by the drug, the adhesive, or other 
excipients in the patch formulation 
More uniform plasma levels The skin's low permeability limits the 
number of drugs that can be delivered in 
this manner 
Useful for drugs that require relatively 
consistent plasma levels  
 
It is an alternative route of administration 
to accommodate patients who cannot 
tolerate oral dosage forms (specially for 
nauseated or unconscious patients) 
 
Improved bioavailability 
 
 
Reduction of side effects  
Flexibility of terminating the drug 
administration by simply removing the 
patch from the skin 
 
Table 1. Main advantages and disadvantages of transdermal drug delivery 
6. Nanocarrier systems 
Nanocarriers have demonstrated increased drug absorption, penetration, half-life, 
bioavailability, stability, etc. Nanocarriers are so small to be detected by immune system 
and they can deliver the drug in the target organ using lower drug doses in order to 
reduce side effects. Nanocarriers can be administrated into the organisms by all the 
routes; one of them is the dermal route. The nanocarriers most used and investigated for 
topical/transdermal drug delivery in the pharmaceutical field are shown in Figure 3 and 
Table 2. 
6.1. Nanoparticles 
Nanoparticles are smaller than 1,000 nm. Nowadays, it is possible to insert many types of 
materials such as drugs, proteins, peptides, DNA, etc. into the nanoparticles. They are 
constructed from materials designed to resist pH, temperature, enzymatic attack, or other 
problems [81]. Nanoparticles can be classified as nanospheres or nanocapsules (See Figure 
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4). Nanospheres are solid-core structures and nanocapsules are hollow-core structures. 
Nanoparticles can be composed of polymers, lipids, polysaccharides and proteins [82,83]. 
Nanoparticles preparation techniques are based on their physicochemical properties. They 
are made by emulsification-diffusion by solvent displacement, emulsification-
polymerization, in situ-polymerization, gelation, nanoprecipitation, solvent 
evaporation/extraction, inverse salting out, dispersion polymerization and other derived 
from these one. 
 
Figure 3. More used transdermal nanocarriers 
6.2. Nanoemulsions 
Nanoemulsions are isotropic dispersed systems of two non miscible liquids, normally 
consisting of an oily system dispersed in an aqueous system (o/w nanoemulsion), or an 
aqueous system dispersed in an oily system but forming droplets or other oily phases of 
nanometric sizes (100 nm). They can be stable (methastable) for long times due to the 
extremely small sizes and the use of adequate surfactants. Nanoemulsions can use 
hydrophobic and hydrophilic drugs because it is possible to make both w/o or o/w 
nanoemulsions [84]. They are non-toxic and non-irritant systems and they can be used for 
skin or mucous membranes, parenteral and non parenteral administration in general and 
they have been used in the cosmetic field. Nanoemulsions can be prepared by three 
methods mainly: high-pressure homogenization, microfluidization and phase inversion 
temperature. Transdermal delivery using nanoemulsions has been reduced due to the 
stability problems inherent to this dosage form.  
More used 
carriers for 
transdermal 
drug delivery.
Nanoparticles
Liposomes Dendrimers
Nanoemulsions
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Figure 4. Nanospheres and nanocapsules are small vesicles used to transport drugs. Nanospheres are 
typically solid polymers with drugs embedded in the polymer matrix. Nanocapsules are a shell with an 
inner space loaded with the drug of interest. Both systems are useful for controlling the release of a 
drug and protecting it from the surrounding environment. 
6.3. Liposomes 
Liposomes are hollow lipid bilayer structures (Figure 5) that can transport hydrophilic 
drugs inside the core and hydrophobic drugs between the bilayer [85]. They are structures 
made of cholesterol and phospholipids. They can have different properties depending on 
the excipients included and the process of their elaboration. The nature of liposomes makes 
them one of the best alternatives for drug delivery because they are non-toxic and remain 
inside the bloodstream for a long time. Liposomes can be surface-charged as neutral, 
negative or positive, depending on the functional groups and pH medium. Liposomes can 
encapsulate both lipophilic and hydrophilic drugs in a stable manner, depending on the 
polymer added to the surface [86]. There are small unilamellar vesicles (25 nm to 100nm), 
medium-sized unilamellar vesicles (100 nm and 500nm), large unilamellar vesicles, giant 
unilamellar vesicles, oligolamellar vesicles, large multilamellar vesicles and multivesicular 
vesicles (500 nm to microns). The thickness of the membrane measures approximately 5 to 6 
nm. These shapes and sizes depend of the preparation technique, the lipids used and 
process variables. Depending on these parameters, the behavior both in vivo and in vitro 
can change and opsonization processes, leakage profiles, disposition in the body and shelf 
life are different due to the type of liposome [86].  
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Liposomes preparation techniques follow three basic steps with particular features 
depending on safety, potential scale up and simplicity: 1) Lipid must be hydrated, 2) 
Liposomes have to be sized and 3) Nonencapsulated drug has to be removed. The degree of 
transdermal drug penetration is affected by the lamellarity, lipid composition, charge on the 
liposomal surface, mode of application and the total lipid concentrations [87].  
 
Figure 5. Liposomes are spherical vesicles that comprise one or more lipid bilayer structures enclosing 
an aqueous core. They protect encapsulated drugs from degradation. Liposomes can also be functionalized 
to improve cell targeting and solubility 
6.4. Dendrimers 
Dendrimers are monodisperse populations that are structurally and chemically uniform 
(Figure 6). They allow conjugation with numerous functional groups due to the nature of 
their branches. The amount of branches increases exponentially and dendrimers growth is 
typically about 1 nm per generation [88]. The dendrimers classification is based on the 
number of generations. After the creation of a core, the stepwise synthesis is called first 
generation; after that, every stepwise addition of monomers creates the next generation. This 
approach allows an iterative synthesis, providing the ability to control both molecular 
weight and architecture.  
The kind of polymer chosen to construct the dendrimer by polimerization is very important 
with regard to the final architecture and features. In addition, the use of branched 
monomers has the peculiarity of providing tailored loci for site-specific molecular 
recognition and encapsulation. Notably, 3D and fractal architecture, as well as the 
peripheral functional groups, provide dendrimers with important characteristic physical 
and chemical properties. In comparison with linear polymers, dendritic structures have 
“dendritic voids” that give these molecules important and useful features. These spaces 
inside dendrimers can mimic the molecular recognition performed by natural proteins. 
 
Recent Advances in Novel Drug Carrier Systems 214 
Furthermore, dendrimers have a high surface-charge density due to ionizable groups that 
help them to attach drugs by electrostatic forces, regardless of the stoichimetry. This 
dendrimer-drug association provides drugs with better solubility, increasing their transport 
through biological membranes and sometimes increasing drug stability. The number of 
molecules that can be incorporated into dendrimers is related to the number of surface 
functional groups; therefore, later-generation dendrimers are more easily incorporated into 
dendritic structure. However, not all the functional groups are available for interaction due 
to steric volume, molecule rotation or stereochemistry effects. Dendrimers can have positive 
and negative charges, which allows them to complex different types of drugs [89].  
 
Figure 6. Dendrimers are highly branched polymers with a controlled three-dimensional structure 
around a central core. They can accommodate more than 100 terminal groups. 
6.5. Advantages and limitations of using nanocarriers for transdermal drug 
delivery 
As it is has been mentioned before, the search for new strategies able to enhance the topical 
and transdermal penetration of drugs has become essential [61]. Different carrier systems 
have been proposed in an attempt to favour the transport of drugs through the skin, 
enabling drug retention and in some cases allowing a controlled release. Skin penetration is 
essential to a number of current concerns, for example, contamination by microorganisms 
and chemicals, drug delivery to skin (dermatological treatments) and through skin 
(transdermal treatments), and skin care and protection (cosmetics) [103-106]. 
Follicular penetration has become a major focus of interest due to the drug targeting to 
the hair follicle is of great interest in the topical treatment of skin diseases. However due 
to follicular orifices only occupying ∼0.1% of the total skin surface area, it was assumed as 
a non important route. But recently, a variety of studies have shown that the hair follicles 
represent a important way to trough the skin and some techniques have been used to test 
the penetration of drugs loaded nanoparticles/microsparticles [70,72,73,107-109]. Confocal 
laser scanning microscopy which permits optical sectioning of thick tissues and cells and 
their subsequent computerized three-dimensional reconstruction, has been used to study 
the entry of drugs through the skin [110]. It was visualized in the fresh human scalp skin 
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on-line the diffusion processes of a model fluorophore into the hair follicle at different 
depths [72]. Such follicular pathway also has been proposed for topical administration of 
nanoparticles and microparticles using porcine skin. Recent studies have confirmed that 
the in vitro penetration into the porcine hair follicles might be considered similar to those 
on humans in vivo [73]. Studies in porcine skin revealed in the surface images that 
polystyrene nanoparticles accumulated preferentially in the follicular openings, this 
distribution was increased in a time-dependent manner, and the follicular localization 
was favored by the smaller particle size [76]. In other investigations, it has been shown by 
differential stripping the influence of size microparticles in the skin penetration. It can act 
as efficient drug carriers or can be utilized as follicle blockers to stop the penetration of 
topically applied substances [75]. An alternative technique is multiphoton microscopy 
(MPM) especially two-photon excitation microscopy has been widely used in imaging 
biological specimens treated with nanoparticles [111-114]. The near-infrared light used in 
the two-photon microscope can penetrate deeper in highly scattering tissues such as in 
vivo human skin than confocal microscopes operated with ultraviolet excitation [115]. 
Futhermore, this technique provides both cellular and extracellular structural 
information, with subcellular resolution helpful for clinical dermatological diagnosis, both 
ex vivo and in vivo. In addition, it can be used to characterize stratum corneum structures, 
visualize and quantify transcutaneous drug delivery, detect skin cancers, explore collagen 
structural transitions, and watch laser–skin interactions [116,117]. A common method 
used for quantifying drugs localized within the skin or various layers of the skin are the 
tape stripping and cyanoacrylate skin surface biopsy techniques, which have been used to 
remove the part of the stratum corneum containing dye topically applied. Thus, the 
"differential stripping" has been shown as a new method that can be used to study the 
penetration of topically applied substances into the follicular infundibula non-invasively 
and selectively [118]. It has been reported in a previous in vitro permeation studies using 
tape stripping, that triclosan-loaded nanoparticles penetrated into the skin and their 
retention favoured a local effect. Moreover, polymeric nanoparticles are expected to be 
able to form a depot in the hair follicles, providing a targeted controlled drug delivery 
[33,119]. 
In general, the principal advantages of microparticles and nanoparticles over conventional 
formulations such as creams, solutions, ointments, lotions, gels, and foams, is that the 
second ones have different absorption characteristics and aesthetic properties, and they also 
have some major limitations, such as poor penetration and uncontrolled drug release. 
Furthermore, tolerability and safety end points, such as irritation, dryness, erythema, 
itching, stinging and burning will be key factors in determining its usefulness. It happens 
because using a traditional system, drug delivery is sometimes rapid and topical or 
plasmatic concentrations can result in toxic effects. However, for the case of nanoparticles a 
smaller amount of the drug is necessary and due to the targeted nature of delivery [120]. 
Topical or transdermal drug deliveries have many advantages over the other routes: fewer 
side effects, increased patient compliance, controlled release, and the lack of a hepatic first 
pass [121]. 
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Nanocarrier Size range Preparation methods Characteristics References 
Polymeric 
nanoparticles 
10-1000 
nm 
-In situ polymerization
-Emulsification-
evaporation, 
-Emulsification-
diffusion, 
-Emulsification-
diffusion by solvent 
displacement. 
Solid or hollow 
particles wich have 
entraped, binded or 
encapsulated drugs. 
[33] 
Solid lipid 
nanoparticles 
50-1000 
nm 
-High-pressure 
homogenization. 
Similar to polymeric 
nanoparticles but 
made of solid lipids. 
[90] 
Inorganic 
Nanoparticles 
<50nm -Sol-gel technique Nanometric particles, 
made up of inorganic 
compounds such as 
silica, titania and 
alumina. 
[91] 
Liposomes 25 nm-100 
µm 
-Sonication 
-Extrusion, 
-Mozafari method 
Vesicles composed of 
one or more concentric 
lipid bilayers, 
separated by water or 
aqueous buffer 
compartments. 
[92] 
Dendrimers 3–10 nm -Polymerization Macromolecular high 
branched structures. 
[93]  
Quantum dots 2-10nm -Colloidal assembly, 
viral assembly, 
-Electrochemical 
assembly. 
Made up of organic 
surfactants, precursors 
and solvents. 
[94] 
 
Lipid globules 1-100 nm -Emulsification 
espontaneous systems.
Multicomponent fluid 
made of water, a 
hydrophobic liquid, 
and one or several 
surfactants resulting in 
a stable system. 
[95] 
 
Lipid 
microcylinders 
<1 µm -Self emulsification Self organizing system 
in which surfactants 
crystallize into tightly 
packed bilayers that 
spontaneously form 
cylinders. 
[96] 
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Ethosomes <400 nm -Cold method 
-Hot method 
Non invasive delivery 
carriers that enable 
drugs to reach the 
deep skin layers 
and/or the systemic 
circulation. 
[97]  
Aquasomes 60-300 nm -Self-assembling of 
hydroxyapatite by 
coprecipitation 
method 
The particle core is 
composed of 
noncrystalline 
calcium phosphate or 
ceramic diamond, and 
it is covered by a 
polyhydroxyl 
oligomeric film. 
[98] 
Pharmacosomes <200 nm -Hand-shaking 
method 
-Ether-injection 
method 
Pure drug vesicles 
formed by amphiphilic 
drugs. 
[99] 
Colloidosomes 200nm – 
1.5 µm 
-Self-assembly of 
colloidal 
particles at the 
interface of 
emulsion droplets 
Hollow capsules with 
elastic shells. 
[100]  
Niosomes 10-1000 
nm 
-Self-assembly of 
nonionic 
Surfactant 
Bilayered structures 
made of non-ionic 
surfactant 
vesicles. 
[101] 
Nanoemulsions 20-200nm -High-pressure 
homogenization. 
-Microfluidization. 
-Phase Inversion 
temperature 
Submicron emulsions 
o/w or w/o. 
[102] 
Table 2. Examples of nanocarriers used for drug delivery. 
It has been reported that nanoencapsulation of drugs (nano-medicines) increases their 
efficacy, specificity, tolerability and therapeutic index [122-124]. These nano-formulations 
are reported to be superior to traditional medicine with respect to controlled release, 
targeted delivery and therapeutic impact. The targeting capabilities of nanomedicines are 
influenced by particle size, surface charge, surface modification, and hydrophobicity. Of 
these, nanoparticle size distribution is an important factor in determining the interaction 
with the cell membrane and their penetration across physiological barriers, being dependent 
on the tissue, target site and circulation [125]. Example of this are the nanostructured lipid 
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carriers (NLC) by their structure (lipid nanoparticles with solid matrix) increase in loading 
capacity, physical and chemical long-term stability, triggered release and potentially 
supersaturated topical formulations with respect to solid lipid nanoparticles (SLN). Other 
advantages of NLC include improvement in stabilisation of incorporated compounds, 
controlled release, occlusivity, film formation on skin including in vivo effects on the skin. 
Lipid nanoparticles have been observed as a good option for transdermal delivery because 
they can be prepared in different sizes and it is possible to modify surface polarity in order 
to improve skin penetration [126,127]. From the upper skin, nanoparticles can reach deeper 
skin regions because they exhibit mechanical flexion [128].  
Additionaly, transdermal nanocarriers are able to reach target organs because they can be 
attached to antibodies, antigens, vitamins and other molecules to be more specific. 
Nanoparticles can travel largely undetected by the immune system depending of the 
nanocarriers size of the antigen added as well as its composition. So, by hiding functional 
groups or protecting these groups with other molecules, drugs can be released specifically 
in the target organ. Consecuently, nanoparticles can even travel from the skin to lymph 
nodes, representing a promising tool for immunomodulation [129]. One of the first 
strategies for transdermal delivery were the liposomes. The nature of liposomes makes them 
one of the best alternatives for drug delivery because they are non-toxic and remain inside 
the bloodstream for a long time [130-133]. Nevertheless, some factors affect the degree of 
transdermal drug penetration such as the lamellarity, the lipid composition, the charge on 
the liposomal surface, the mode of application and the total lipid concentrations [89,134]. 
For that reason, flexible vesicles called transfersomes or transformable liposomes have been 
compared with those rigid vesicles to enhance penetration [135-142]. The lipids present in 
the liposome bilayer can interact with lipids present in the stratum corneum changing the 
structure of the upper skin. This change is beneficial for the penetration of lipophilic drugs 
into the stratum corneum [143]. Some liposomes may have a deformable structure and pass 
through the stratum or may accumulate in the channel-like regions in the stratum corneum, 
depending upon their composition [144,145]. In order to obtain transformable liposomes 
more flexible, they are prepared using surfactants or alcohol (ethosomes) in the lipid bilayer, 
to be able to deform them when a pressure is applied in the transdermal route. 
Some limitations for nanocarriers are the important tests and regulations that should be 
carried out to ensure an adequate characterization, analytical evaluation, toxicological and 
pharmacological assessment, which is necessary to determine the efficacy of using these 
nanostructures in therapies and diagnosis because of their tiny size, their high surface 
energy, their composition, their architecture, their attached molecules, etc. Those things are 
frequently reviewed for the dendrimers. One of the main advantages is that they have 
multivalency and it is possible to get control of the functional groups on the surface 
[146,147]. Due to their form and size (1–10 nm), these molecules can carry drugs, imaging 
agents, and can interact with lipids present in membranes, because it was reported a better 
permeation in cell cultures and intestinal membranes. They also increased the permeation of 
lipophilic drugs instead of hydrophilic drugs. The main problems with this kind of 
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transdermal carrier are poor biodegradation and inherent cytotoxicity [148]. To obtain 
dendrimers less toxic, dendrimers have been linked to peptides. Dendrimers-peptides are 
formed from amino acids linked via peptide-amide bonds to the branches of dendrimers in 
the core or on the surface to get down the toxicity. Then, they are bio-transformed to 
produce amino-acid derivatives. Besides, the synthesis of these structures is less expensive 
and purification does not present any difficulty [149,150]. 
It is suggested in future research to elucidate the interactions between nanocarriers and 
other molecules as well as interactions between nanocarriers and biological entities. The 
toxicology of nanostructures is also a current concern. Materials behave very differently 
when they are diminished to nanosizes. Traditional laws do not work at this “meso-scale” in 
the same way as they function at the macro-scale. On the macro scale, bulk properties in a 
material predominate over surface properties. At the micro-scale, surface properties tend to 
dominate. At the meso-scale, both types of properties play significant roles [151,152]. 
Furthermore, the effects of metabolized/altered nanostructures on the biological system are 
difficult to predict. Regulatory agencies are taking action to assess new Nanotechnology-
based products. 
In addition, the fabrication of nanocarriers scaling up from the lab at the industrial 
production is difficult and the materials used to prepare nanocarriers are very expensive in 
the majority of the cases.  
7. Applications of nanocarrier systems in topical/transdermal delivery 
Nanocarriers as drug delivery systems were first intended for use in parenteral or oral 
routes of administration and as such still continue to be the focus of many studies [153]. 
However skin application of these nanocarriers, and especially for liposomes, polymeric and 
lipidic nanoparticles, also makes sense when considering surface effects (film formation and 
occlusive effects), local effects in the skin (drug delivery in the epidermis and dermis) and 
systemic effects (deeper drug permeation and transdermal delivery). In potential uses apart 
from those concerned with surface effects the nanocarrier has to overcome the SC barrier in 
order to deliver the drug more or less deeply into skin layers. Recent advances in the study 
of penetration mechanisms deal with the control of the intercellular penetration route by the 
crystalline state of lipids, and the penetration through skin appendages (the follicular 
pathway) that appears to contribute much more than was previously thought. Applications 
dependent on skin penetration that have received special attention include transdermal 
delivery of nano- and microparticles by hair follicles, especially for nanoparticles which 
penetrate hair follicles very efficiently targeting the skin immune system in order to develop 
new vaccination strategies, and problems relating to skin diseases [154,155]. 
Options for topical and transdermal delivery are the solid lipid nanoparticles (SLNs) and 
nanostructured lipid carriers (NLCs) [156]. Some drugs such as triptolide, triamcinolone 
acetonide acetate, cyclosporin A have been used to be entrapped in SLN [157-159]. SLN can 
be admixed to an already commercially available and established topical formulation, e.g. a 
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cosmetic day cream. Admixing the SLN leads to an increase in occlusivity while still 
maintaining the ‘light character’ of the day cream and avoiding the glossiness of more 
occlusive night creams. This phenomena is explained in Figure 7. However, having a highly 
occlusive night cream already, addition of SLN will have little or no effect [156].  
Lipid nanoparticles are other options to load arthemeter and econazole nitrate [160,161]. 
Celecoxib [162]. It was compared the permeability of coenzima Q 10 incorporated in NLC 
and in an emulsion with the same lipid contain. The occlusion effect of the cream was also 
investigated. The result showed a higher permeability of the molecule and a higher 
occlusive effect for the NLC than for the emulsion as it could be observed in Figures 8 and 9 
[163].  
 
Figure 7. The occlusion factor of lipid nanoparticles depends on various factors: at identical lipid 
content, reducing the particle size leads to an increase in particle number, the film becomes denser (left) 
and therefore the occlusion factor increases. At a given particle size, increasing the lipid concentration 
increases particle number and density of the film (right) which also leads to a higher occlusion factor. 
Different studies shown lipid nanoparticles were able to enhance the chemical stability of 
compounds sensitive to light, oxidation and hydrolysis. Enhancement of chemical stability 
after incorporation into lipid nanocarriers was proven for many cosmetic actives, e.g. 
coenzyme Q10 [164-166], ascorbyl palmitate [164,167], tocopherol (vitamin E) [165] and 
retinol (vitamin A) [168-170]. 
Three vitamin derivatives including vitamin C (ascorbyl tetraisoplamitate), vitamin E 
(tocopherol acetate) and vitamin A (retinyl palmitate) were also loaded in PLGA 
nanospheres, for skin whitening and anti-wrinkles/aging applications due vitamin C 
suppresses the blemishes because it limits the activity of tyrosinase, which promotes 
melanin production. Furthermore, it increases collagen formation to reduce wrinkles, and 
prevents cell oxidation by eliminating active oxygen. As to vitamin E and A, they also act as 
antioxidant and collagen promoter, respectively. They were able to reach the target areas in 
a stable form, sustain the pharmacological effect for a long time and be effective to reduce 
the wrinkles and produce a whitening effect [171]. In a sense, the idea of nanoparticle design 
for drug delivery systems in cosmetics applications is important.  
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Figure 8. Occlusion factor (F) of NLC, emulsion and liquid paraffin (with permission from authors) [163]. 
 
Figure 9. Tape stripping test: summation of coenzyme Q10 found in the tapes related to the applied 
amount (with permission from authors) [163]. 
As it was described before, the follicles are deep invaginations inside skin where the SC is 
thinner, the vascularisation is denser, and there are several targets of interest along a follicle 
structure from both cosmetic and pharmaceutical viewpoints [172]. Here, minoxidil which is 
an antihypertensive has been introduced in a block of copolymer poly (-caprolactone)-
block-poly(ethyleneglycol) to treat the alopecia areata disorder , by widening blood vessels 
and opening potassium channels, it allows more oxygen, blood, and nutrients to the follicle. 
This disorder is an inflammatory condition, often reversible hair loss affecting mainly 
children and young adults. Clinically, round hairless patches appear on the scalp while hair 
follicles remain intact. This skin disorder is related with the distal part of the human hair 
follicle immune system, especially with the interacting intraepithelial T cells. The cause of 
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this condition is diverse and seems to involve T cell–mediated immunologic changes, 
neuropeptides, genetic disposition to autoimmunity, and distress [30,173,174]. As the 
infundibulum of the hair follicle is surrounded by an extensive capillary network and the 
permeability of its epithelium allows the transport of molecules or particles to the blood 
circulatory system. There is a high density of immune cells in and around the infundibulum 
epithelium which could be targets also for hair follicle immune system and topical 
vaccination.  
The sebaceous glands associated with hair follicles provide another potential target for 
delivering drugs against acne, androgenetic alopecia and other sebaceous gland 
dysfunctions. Different nanoparticles formulations have been prepared in order to treat acne 
vulgaris, which is an inflammatory disease of the pilosebaceous units, most densely 
concentrated on the face and torso [175]. Pathogenesis is multifactorial, but Propionibacterium 
acnes a Gram-positive bacterium plays a central role in the promotion of inflammation in 
acne. The most commonly formulations are prepared with different topical antimicrobials, 
either alone or in combination with other drugs. It is expected that an agent able to inhibit P. 
acnes growth and to suppress the inflammatory response will provide significant benefits to 
patients with acne vulgaris [30,176,177]. For that reason triclosan has been used in several 
systems. It was reported the characterization of triclosan loaded polymeric nanoparticles. 
They showed a good encapsulation efficiency and also a good physical stability representing 
an alternative as a treatment of acne [33]. Triclosan loaded nanoparticles made of chitosan 
and cyclodextrins were prepared using a very simple ionic gelation technique. This new 
approach permits to enhance the entrapment of hydrophobic drugs by forming molecular 
inclusion complexes with cyclodextrins in aqueous media. Such a device could be of interest 
for conferring protection to some specific drug molecules through the complexation 
followed by entrapment in the polymer matrix [109]. Another drug used to treat this 
disorder is tretinoin (all-trans-retinoic acid) which is the active form of a metabolic product 
of Vitamin A, also called retinoic acid. Tretinoin-loaded nanocapsules improved tretinoin 
photostability, independently on the type of oily phase used (capric/caprylic triglycerides 
and sunflower seed oil) in this study, and represent a potential system to be incorporated in 
novel topical or systemic dosage forms containing tretinoin [178]. 
Formulations of nanoparticles are often used in combination with penetration chemical and 
physical enhancers to modify the physical state of the stratum corneum, affecting the degree 
of transdermal drug penetration. DNA has been entrapped in nanoparticle of 
polysaccharide such as chitosan/poly--glutamic acid and in a multifunctional core-shell 
polymeric nanoparticle of PLGA core and a positively-charged glycol chitosan (GC) shell. 
Another drugs used in the preparation of nanoparticles made of propyl-starch derivatives 
are flufenamic acid, testosterone and caffeine [179,180]. Insulin is a protein which has also 
been introduced in chitosan nanoparticles [83]. Poly (lactide-co-glycolide) polymer has been 
used to prepare biodegradables nanoparticles containing dexamethasone phosphate and 5-
Fluorouracil [181,182]. Chlorhexidine loaded polymeric nanoparticle are used to treat 
cutaneous infections [183]. 
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Inflammatory skin diseases account for a large proportion of all skin disorders and 
constitute a major health problem worldwide. Psoriasis, atopic dermatitis, poison ivy, and 
eczema are another skin disorders. Contact dermatitis, atopic dermatitis, and psoriasis 
represent the most prevalent inflammatory skin disorders and share a common efferent T-
lymphocyte mediated response. Oxidative stress and inflammation have recently been 
linked to cutaneous damage in T-lymphocyte mediated skin diseases, particularly in contact 
dermatitis [184]. Poison ivy and atopic dermatitis may also present with bullous and 
vesicular changes [185]. Lipid nanoparticles have been investigated to improve the 
treatments of skin diseases such as atopic eczema, psoriasis, skin mycosis and 
inflammations. Apart from the treatment of skin diseases by topical application, e.g. 
gastrointestinal side effects of non-steroidal anti-inflammatory drugs can be decreased by 
topical antirheumatic therapy. Drugs under investigations for dermal application using lipid 
nanoparticles at the present are for instance glucocorticoids, retinoids, non-steroidal anti-
inflammatory drugs, COX-2 inhibitors and antimycotics. It was showed that it is possible to 
enhance the percutaneous absorption with lipid nanoparticles. These carriers may even 
allow drug targeting to the skin or even to its substructures. Thus they might have the 
potential to improve the benefit/risk ratio of topical drug therapy [186]. 
Perioral dermatitis is commonly seen in women aged 20–35 years. It presents as red papules 
that form superficial plaques around the perioral area, nasolabial folds and/or lower eyelids. 
It is minimally itchy [187,188]. Topical corticosteroids are the first-line therapy of acute 
exacerbations of atopic dermatitis and contact dermatitis. Prednicarbate is superior to the 
halogenated glucocorticoids because of an improved benefit/risk ratio. However, at the 
present the separation of desired anti-inflammatory effects and undesired antiproliferative 
effects is still not satisfying. Therefore, lipid nanoparticles were investigated as a delivery 
system for prednicarbate. The report show an improved extent of prednicarbate uptake by 
human skin in vitro, if applied as SLN dispersion or cream containing prednicarbate-loaded 
SLN. The authors found that a prednicarbate targeting to the epidermis [189]. This is 
particular relevant because prednicarbate in the dermis is responsible for the induction of 
irreversible skin atrophy while the inflammatory process is most pronounced within the 
epidermis [186]. Therefore, a better benefit/risk ratio is expected for the application of 
pretnicarbate in SLN containing topical formulations. 
Tretinoin, a metabolite of vitamin A is used for topical treatment of various proliferateive 
and inflammatory skin diseases such as psoriasis, acne (as mentioned before), photo aging, 
epidermotropic T-cell lymphomas and epithelial skin cancer. One of the major 
disadvantages associated with the topical application of tretinoin is local skin irritation such 
as erythrema, peeling and burning as well as increased sensitivity to sunlight. To overcome 
these problems tretinoin was incorporated into SLN [190]. In vitro permeation studies 
through rat skin indicated that SLN-based tretinoin gel has a permeation profile comparable 
to that of the market tretinoin cream. Furthermore, Draize patch test showed that SLN-based 
tretinoin gel resulted in remarkably less erythremic episodes compared to the currently 
marketed tretinoin cream (Figure 10). Therefore, also for formulations containing tretinoin-
loaded SLN a better benefit/risk ratio is expected.  
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Figure 10. Pictures of Draize skin irritation studies carried out on New Zealand rabbits 24 h after 
application of (A) control (no application); (B) marketed formulation (Retino-A® cream); (C) SLN-based 
gel without tretinoin; (D) SLN-based gel containing tretinoin (0.05%, w/w). The Marketed tretinoin 
cream clearly shows erythemal lesions, which are not visible in SLN based tretinoin gel [190]. 
“Reprinted from International Journal of Pharmaceutics, 345/1-2, Kumar A. Shah, Abhijit A. 
Date,Medha D. Joshi,Vandana B. Patravale, Solid lipid nanoparticles (SLN) of tretinoin: Potential in 
topical delivery, 163-171., Copyright (2007), with permission from Elsevier” 
Liposomes which were one of the first strategies for transdermal delivery are being 
successfully used in cancer therapy [139,141]. However to date, many liquid-type 
nanocosmetics carriers, such as liposomes, are structurally unstable. Specifically, when 
passing through the skin, they adhere to the inside walls of the skin cells causing the 
collapse of phospholipid association bodies and the leak of their encapsulated ingredients. 
As a result, their ability to transport active ingredients to deep skin is not likely good. Some 
authors report the use of flexible vesicles called transfersomes or transformable liposomes in 
comparison with rigid vesicles to enhance penetration [148,191]. The application of 
transformable liposomes more flexible, which are prepared using surfactants or alcohol 
(ethosomes) in the lipid bilayer, to be able to deform them when a pressure is applied in the 
transdermal route has been increased. 
In some researches, dendrimers are used for transdermal drug delivery. They show 
promising results in the delivery of drugs such as tamsulosin [192], indomethacin [193], 
ketoprofen and diflunisal [194 ] and 5-fluorouracil [195]. The main problems with this kind 
of transdermal carrier are poor biodegradation and inherent cytotoxicity [158]. In order to 
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get down the toxicity dendrimers have been linked to peptides (dendrimers-peptides) from 
amino acids linked via peptide-amide bonds to the branches of dendrimers in the core or on 
the surface [159,160].  
For 5-fluorouracil (5FU) (log P = −0.89) which is one hydrophilic model drug used to treat 
skin diseases, has been reporte to have very poor penetration in skin [196-198]. Many 
strategies to increase skin permeation of this drug have been tested: prodrugs, terpenes, 
fatty acids, iontophoresis, sonophoresis, laser ablation and dendrimers which increased 5FU 
permeation across the skin by altering the skin structure [198-203]. 
Nowadays transdermal delivery using nanoemulsions it is not so used as nanoparticles or 
liposomes delivery due to the stability problems inherent to this dosage form. Nevertheless, 
Gamma Tocopherol, Caffeine, Plasmid DNA, Aspirin, Methyl Salicylate, Insulin, 
Nimesulide have been included in nanoemulsion. The use of these nanocarriers to deliver 
analgesics, corticosteroids, anti cancer agents, etc. is very important since these drugs are 
able to act immediately because they do not need to cross extra barriers. The drug is 
bioavailable easily and faster [204-210]. 
8. Conclusions 
Nanocarriers have shown many advantages for topical and trasdermal delivery of drugs. It 
could be shown already for various drugs that topical/trandermal formulations containing 
nanoparticles can enhance the penetration into the skin increasing treatment efficiency, 
target the epidermis or follicles, reducing side effects. Furthermore, an increased activities as 
well as prolonged activities have been reported. These delivery systems can deliver both 
hydrophilic and lipophilic molecules. Advances with regard to materials, fabrication 
methods and techniques facilitate the development of new and better nanocarriers. 
Nonetheless, future researches must ensure the benefit and evaluate the risk ratio for many 
drugs included in nanocarriers.  
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